Back Refine search Reset
Please choose a search criteria from below
Filters Clear all
Specialties
Treatments

100+ results found in London, UK

Sort by:
Showing 31 - 40 of 100+ results
Oncology
Offers video consultation
28 years of experience
Breast Cancer, Clinical Oncology, Medical Oncology

Dr Hadaki is an experienced Consultant Oncologist who treats all stages of breast cancer.

He completed his specialist oncology training at Addenbrooke’s Teaching Hospital which has strong affiliations to the University of Cambridge. During his training, he completed the Royal College of Radiologist membership exam to proudly become one of its fellowships.

Dr Hadaki has been practising as a consultant since 2012 and has a very successful private practise in addition to his large well-established NHS practice.

Dr Hadaki is skillfully able to combine (where appropriate) the following treatment modalities to offer a complete and state of the art personalised cancer treatment service:

  • Chemotherapy
  • External beam radiotherapy (including IMRT and IGRT)
  • Biological and targeted therapies
  • Immunotherapies
  • Stereotactic radiotherapy (SBRT, SABR, Cyberknife)
  • Next-generation sequencing and molecular analysis of tumours
  • Chemotherapy sensitivity testing
  • Access to clinical trials
  • Access to local ablative therapies (radiofrequency ablation, microwave ablation)
  • Access to alternative therapies
  • Access to palliative care services

Dr Hadaki also works with some of the most skilled surgeons in the country. All treatment plans are discussed at multidisciplinary team meetings.

Dr Hadaki is registered and compliant with the majority of private medical insurers including BUPA, BUPA International, AXA, Aviva, Vitality, WPA and others.

Dr Hadaki is able to treat international and self-paying patients. Embassy sponsored patients must have a letter of guarantee before any consultation or commencing treatment.

Self-paying patients should contact us directly for a quotation.


Diseases, Medical Tests and Treatments

  • Breast Cancer
  • Lung Cancer
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy
  • Stereotactic ablative radiotherapy (SABR)
  • Oncology
  • Breast Cancer


Read more
Oncology
Recommended by 1 specialist
23 years of experience
Breast Cancer, Medical Oncology

Dr Kristeleit completed his undergraduate studies at the Universities of Bonn (Germany), Lausanne (Switzerland) and Barts and The London School of Medicine. He has a first class medical degree from Bonn University and performed his post graduate and specialist training in London teaching hospitals. He spent four years as an AVON Clinical Research Fellow at the Breakthrough Breast Cancer Research Centre investigating novel targets in familial breast cancer. He was appointed as a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust in 2009.

He has a special interest in breast cancer and Acute Oncology. He provides the medical oncology service for breast cancer at Queen Elizabeth and Queen Mary's hospitals and is currently the lead clinician for Acute Oncology in the South East London Accountable Cancer Network. Dr Kristeleit has a keen research interest in the role of novel therapies for breast cancer. He is an investigator on numerous clinical trials for breast cancer and chairs the oncology research committee at Guy's and St Thomas'.

He gives regular lectures for the University of London and has been invited to speak at national conferences and international meetings. He specializes in the treatment of early and advanced breast cancer.


Diseases, Medical Tests and Treatments

Read more
Oncology
31 years of experience
Breast Cancer, Medical Oncology, Advanced Melanoma

 

Dr Mark Harries is a Consultant Medical Oncologist at Guy's & St Thomas' Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine - he also sees patients privately. He specialises in the treatment of breast cancer and melanoma.

Dr Harries graduated from Cambridge University and underwent clinical training at the Royal London Hospital. He then trained in medical oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College, London. His research interests include immunotherapy for melanoma and breast cancer as well as clinical trials of new biological agents for these diseases.

He has published many papers and presents on a regular basis at national and international conferences. He is the Oncology Editor for the International Journal of Clinical Practice. Dr Harries is also an honorary senior lecturer at King's College London School of Medicine. 

Diseases, Medical Tests and Treatments

  • Chemotherapy
  • Immunotherapy
  • Biological therapy
  • Hormonal therapy
  • Breast Cancer
  • Melanoma

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

 

Read more
Oncology
52 years of experience

Dr Peter Harper trained at University College and University College Hospital (MB BS 1970) and has been a leading consultant at Guy's and St Thomas Hospital for over 25 years. He is both an accredited physician and a medical oncologist. One of the four founder partners of the London Oncology Clinic, his vision was of a clinic dedicated solely to cancer treatment offering the highest international standards of care in a state-of-the-art supportive environment, also providing the support including all the ancillary care required by patients and their families.

Author of more than 400 papers and chapters in peer-reviewed publications, he is acknowledged globally for his work in researching new drugs and developing improved forms of cancer treatment. He has been the chair, or has been a member of many international executive committees investigating new approaches to cancer treatment, editorial boards for professional publications and is currently a member of eight pharmaceutical company advisory boards and is a member of sixteen professional bodies from around the world, including board membership of a committee of the American Society of Clinical Oncologists (ASCO).

In 2002 he was awarded the prestigious Cino del Duca Medal in 2004 in recognition of his work in developing new anti-cancer and vaccine therapies. For his role in advising the French Government in strategic cancer care (Board Member French National Cancer Institute), he was appointed a Chevalier of the Legion D'Honneur, a rare distinction for a foreign national. He remains on the board of INCA, the strategic committee for cancer treatment in France, and is currently the Chairman of the Toulouse Cancer Centre and holds the Medaille D'Or of that city.


Diseases, Medical Tests and Treatments
  • Chemotherapy of solid tumours
  • Gynaecological cancers
  • Gastrointestinal cancers
  • Breast cancer
  • Lung cancer
  • Urological cancers
  • Chemotherapy of solid tumours
  • Gynaecological cancers
  • Gastrointestinal cancers
  • Breast cancer
  • Lung cancer
  • Urological cancers
Read more
Oncology
26 years of experience
Medical Oncology, Endometrial Cancer, Ovarian Cancer + 5more

Dr Rebecca Kristeleit specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy's and St Thomas' NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy's Clinical Research Facility. She currently leads a large portfolio of Phase I-III clinical studies including immunotherapy for gynaecological malignancies.

Dr Kristeleit qualified in 1995 from the University of Manchester after initially completing a BSc in medical science at the University of St Andrews. As an undergraduate, she was awarded an ERASMUS Scholarship which allowed her to study in Switzerland before completing an elective at Massachusetts General Hospital, Harvard University. She specialised in medical oncology at the Royal Marsden Hospital and obtained a CRUK-funded clinical research fellowship at the Institute of Cancer Research, being awarded a PhD in the clinical pharmacology of HDAC inhibitors.  She completed a Senior Fellowship at the Royal Marsden Hospital's Drug Development Unit in 2009 where she gained experience in experimental therapeutics. She was appointed Clinical Senior Lecturer and Honorary Consultant Medical Oncologist at UCL in 2009 and subsequently Associate Professor in Experimental Therapeutics at UCL.

Dr Kristeleit is a member of the Target Ovarian Cancer Scientific Advisory Board, the Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, and has been elected to the ESMO Faculty from 2021 to 2025. She has over 100 peer-reviewed publications and is often asked to speak at national and international conferences as well as advise pharmaceutical companies on their gynaecological cancer drug development.

Dr Kristeleit has previously served as Chair of the BGCS Scientific Committee, the UK Oncology Forum Gynaecology Track, and the ASCO Gynaecological Cancer Scientific Committee.

Read more
Oncology
19 years of experience
Medical Oncology

Deborah Enting is a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust and an Honorary Senior Lecturer at King's College London.

She undertook her medical training at the University of Groningen in The Netherlands and trained in Medical Oncology at Guy's and St George's Hospitals. She was a research fellow at the Department of Immunobiology at King's College London and in collaboration with colleagues of the Translational Oncology Urology Research (TOUR) group at KCL she works on tumour immune surveillance and bladder cancer research.

Deborah is a Medical Oncologist specialising in the treatment of Urological Cancers and the systemic treatment (chemotherapy, immunotherapy and targeted therapies) for bladder, prostate, kidney and testicular cancers. She is a national lead on a number of clinical trials including the IRONMAN prostate cancer registry study.

 


Diseases, Medical Tests and Treatments
  • Bladder cancer
  • Prostate cancer
  • Kidney cancer
  • Testicular cancer
  • Bladder cancer
  • Prostate cancer
  • Kidney cancer
  • Testicular cancer
Read more
Oncology
35 years of experience
Clinical Oncology

George Mikhaeel is a Professor of Radiation Oncology at King’s College London and Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Foundation Trust since 2001. He specialises in the treatment of lymphoma with both chemotherapy and radiotherapy and has extensive experience in advanced radiotherapy techniques for haematological malignancies.

Professor Mikhaeel’s research has resulted in new ways of treating lymphoma patients with radiotherapy, harnessing the benefits of advances in radiotherapy technology and advances in imaging. An example of new treatments is combining an innovative arc technique and deep inspiration breath-hold (DIBH) with image-guided delivery of treatment to improve the accuracy of targeting radiation and reduce dose to healthy tissues.

His clinical practice is focused only on haematological malignancies which are less common and require a high level of specialisation and substantial clinical experience, having practised in this field for more 20 years. Professor Mikhaeel has lectured in more than 15 countries and has numerous publications in the field including four influential international guidelines.

He is a founding member of the International Lymphoma Radiation Oncology Group (ILROG) and a member of its steering and executive committees. Professor Mikhaeel also chairs the haematology track for the American Society of Radiation Oncology (ASTRO) annual meeting scientific committee and a reviewer for the European Society of Radiation Oncology (ESTRO). Nationally, he is the chair of the UK Lymphoma Radiotherapy Group (UK-LRG) steering committee.


Diseases, Medical Tests and Treatments


  • Radiotherapy
  • Chemotherapy


  • Haematological malignancies
Read more
Oncology
35 years of experience

Dr Paula Wells oncology training was undertaken at St. Bartholomew's, UCLH, and Mount Vernon Hospitals; following her Fellowship, she undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith Hospital. There she investigated the potential for Positron Emission Tomography (PET) to demonstrate the biological effects of chemotherapy in tissue for which she received a number of awards. She has published a number of papers in this area and was awarded a Ph.D. for her work. Subsequently, she completed her post-doctoral training at the Royal Marsden Hospital, principally with the Academic Urology Unit.

Dr Wells specializes in the management of patients with genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies and has expertise in all non-surgical treatments including chemotherapy, immunotherapy, biological and targeted therapies. She utilises state-of-the-art radiotherapy techniques including image-guided (IGRT), intensity-modulated radiotherapy (IMRT), 4D CT, and Stereotactic Radiotherapy (SABR and SRS) using both Cyberknife and Linear accelerator platforms. In addition, she has extensive experience of low dose rate brachytherapy (LDR) in the management of prostate cancer.

Since taking up her present NHS post she has been extensively involved with the development of the genitourinary and thoracic cancer services for the North East London Cancer Network.

Dr Wells has an active trial portfolio of UK clinical trials and is the principal investigator for a number of pivotal radiotherapy studies. From these activities, she took a clinical lead in the development of IMRT for prostate cancer, chemo-radiation in bladder and lung cancer and Stereotactic Radiotherapy (SABR) at Barts Health. Her research interest in Positron Emission Tomography continues to develop with an emphasis on investigating the direct effects of radiotherapy on tissue and the integration of novel therapies with radiation. She is currently Clinical Governance and Audit Lead for Barts Cancer Centre and Chairs the Stereotactic Body MDT.

 


Diseases, Medical Tests and Treatments

  • Urological (bladder, prostate)
  • Lung (including Mesothelioma) cancers (chemotherapy and radiotherapy)
  • Urological (bladder, prostate)
  • Lung (including Mesothelioma) cancers (chemotherapy and radiotherapy)
Read more
Oncology
25 years of experience
Advanced Melanoma, Medical Oncology, Renal Cancer + 1more

Dr Paul Nathan is an internationally renowned and well-respected Consultant Medical Oncologist with HCA Healthcare at LOC, The Harley Street Clinic, and The Wellington Hospital. His NHS practice is based at Mount Vernon Cancer Centre and UCLH. Dr Nathan’s clinical interests include melanoma of the skin, eye, and internal organs; kidney cancer (renal cell carcinoma), and rare skin cancers including Merkel cell carcinoma.

He originally trained in cancer immunology as a scientist, and following his Ph.D. and post-doctoral position in Pittsburgh, he ran a tumor immunology laboratory in the pharmaceutical industry. He then pursued clinical studies at Cambridge and UCL.

Dr Nathan has been a Consultant Medical Oncologist for nearly 20 years. He remains heavily involved in research and is the lead investigator for many clinical trials, particularly in the field of immunotherapy and targeted therapies. Most recently he has led the development of tebentafusp, the first drug proven to improve survival in advanced uveal melanoma. Dr Nathan has published over 100 papers, many of which are in the world’s leading medical journals, and has contributed to a number of medical textbooks. He is the Chair of the UK Uveal Melanoma Guidelines group and the UK Lead for Uveal Melanoma at the International Rare Cancer Initiative. He also leads the melanoma systemic therapies for the European cancer organisation’s (EORTC) melanoma group. Previously, Dr Nathan chaired the NCRI renal cancer clinical studies group. 

 


Diseases, Medical Tests and Treatments

  • Immunotherapy
  • Chemotherapy
  • Urological Cancer
  • Kidney Cancer
  • Renal Cancer
  • Skin Cancer
  • Melanoma
Read more
Oncology
30 years of experience
Medical Oncology

Dr Anne Armstrong is a well-respected Consultant Oncologist with HCA Healthcare and Guy's and St. Thomas' NHS Foundation Trust in London where she is the Head of Medical Oncology, along with being the lead for Systemic Treatment of Breast Cancer in South East London.

She graduated with a degree in Psychology and returned to university to study Medicine at the renowned Imperial College London. She completed her medical oncology training at numerous centres of excellence, including the Royal Marsden Hospital and Hammersmith Hospital. Following this she completed pioneering research into the molecular genetics of breast and pancreatic cancer and was awarded a PhD. In 2005 she was appointed her first Consultant post. She remains heavily involved in research, being appointed as chief investigator and of numerous breast cancer trials.


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Hormonal Therapy
  • Endocrine Therapy
  • Breast Cancer
Read more